Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIA Trial of Rosiglitazone (Avandia) for Oral Leukoplakia

Trial Profile

Phase IIA Trial of Rosiglitazone (Avandia) for Oral Leukoplakia

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2013

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Leucoplakia; Mouth neoplasm
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 24 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Sep 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 24 Jun 2008 Additional trial identifier MDA2005-0485 reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top